Idera Pharmaceuticals, Inc.: Revision history

20 August 2022

• curprev 03:2103:21, 20 August 2022 95.149.241.133 talk 622 bytes +11 No edit summary undo

13 August 2022

• curprev 03:1203:12, 13 August 2022 109.180.50.163 talk 611 bytes +15 No edit summary undo

8 August 2022

• curprev 02:4102:41, 8 August 2022 >Paris 596 bytes +596 Created page with "Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with..."